✦ LIBER ✦

The impact of combination therapy with peginterferon alfa-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients

✍ Scribed by C. Hamer

Book ID: 108861335
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 154 KB
Volume: 21
Category: Article
ISSN: 0952-3871
DOI: 10.1111/j.1365-277x.2008.00882.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A case of hepatitis C-associated osteosc

A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin

✍ Satoshi Shakado; Yuko Akehi; Kaoru Yotsumoto; Atsushi Fukunaga; Shizuka Kuno; Ta 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 393 KB

Impact of IL28B on treatment outcome in

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin

✍ Thomas-Matthias Scherzer; Albert Friedrich Stättermayer; Michael Strasser; Herma 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 502 KB

The IL28B genotype is the most important pretreatment predictor of treatment outcome in patients with chronic hepatitis C. The impact of the rs12979860 genotype on relapse was retrospectively evaluated in genotype 1/4 patients who received response-guided therapy with peginterferon alpha-2a 180 μg/w

Efficacy and tolerability of peginterfer

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

✍ T. Witthoeft; D. Hueppe; C. John; J. Goelz; R. Heyne; B. Moeller; G. Teuber; S. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

Triple combination of thymalfasin, pegin

Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study

✍ JORGE LUIS POO; F SÁNCHEZ-AVILA; D KERSHENOBICH; X GARCÍA-SAMPER; J GONGORA; M U 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

Impact of high-dose peginterferon alfa-2

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

✍ Stuart K. Roberts; Martin D. Weltman; Darrell H. G. Crawford; Geoffrey W. McCaug 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

This study tested the hypothesis that high-dose peginterferon alfa-2a (PEG-IFNalpha-2a) for the first 12 weeks would increase early and sustained virological response (SVR) rates in patients with chronic hepatitis C genotype 1. Eight hundred ninety-six patients were randomized 1:1 to 360 microg (n =

Randomised clinical trial: escitalopram

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C

✍ R. J. de Knegt; G. Bezemer; A. R. Van Gool; J. P. H. Drenth; B. E. Hansen; H. A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB